Imatinib Completed Phase 2 / 3 Trials for Chronic Myeloid Leukemia (CML) / Gastrointestinal Stromal Tumors Treatment

IndicationsStatusPurposePhase
CompletedTreatment2 / 3
clinicaltrials.gov IdentifierTitleDrugs
NCT00500188Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST
NCT00858806Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy
NCT00025246Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
NCT00112632Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
NCT00514969Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase
NCT01267695Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
NCT00219752Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years
NCT01483014Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)
NCT00852566Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia
NCT00028002Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
NCT00455559Ph II Study of Perifosine Plus Gleevec for Patients With GIST
NCT00237172Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
NCT00219726Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation